MGA MedTech: From Research and Development to Industrial Production

MGA MedTech and InsideTX: Industrial Excellence Supporting the RNA Therapy Revolution

In the global biotechnology landscape, France is reinforcing its leadership not only through scientific discovery but also through its capacity to transform these innovations into high-precision industrial instruments. The strategic partnership announced in October 2025 between MGA MedTech and the Deeptech company Inside Therapeutics (InsideTX) for the production of the TAMARA platform is a perfect illustration of this industrialization dynamic.

The Mably Factory: A 4.0 Production Infrastructure

Inaugurated at the end of 2023, the Mably site represents a €10 million investment. This 4,000 m² facility—winner of the 2024 Connected Factory Trophy and labeled a “Vitrine industrie du future” combines industrial architecture with operational performance.

• Advanced Robotics: Logistics management is handled by Autonomous Mobile Robots (AMRs) that supply modular production cells. This organization allows for the production of series ranging from 100 to 1,000 units per year with increased flexibility.

• Environmental Performance: The site operates as a positive-energy building and meets the latest eco-responsible standards through the use of geothermal and photovoltaic energy.

Total Digitalization: The factory deploys a completely paperless production flow. Every manufacturing step is digitally tracked via ERP and EMS systems, ensuring the compliance required for CE and FDA certifications.

MGA MedTech: A Strategic Partner for Industrialized R&D

MGA MedTech acts as a specialist in the industrialization of high-precision medical devices. Its “one-stop-shop” model supports a product throughout its entire life cycle, from the initial proof of concept (TRL 4) to the mass production of certified instruments (TRL 9).

MGA MedTech: From Research and Development to Industrial Production

The company’s offer is structured around three strategic verticals:

• In-Vitro Diagnostics (IVD): Development of complex instruments for biological analysis, including high-precision digital PCR systems.
• Bioprocesses for Innovative Therapies (MTI/ATMP): Equipment for Cell and Gene therapies, including the formulation of viral vectors and lipid nanoparticles.
• Mechatronic Medical Devices: Design of smart and connected Class IIa and III systems, compliant with strict sector-specific regulatory requirements.

Multi-Technological Mastery and Expansion

MGA MedTech mobilizes expertise in microfluidics, optronics, robotics, and artificial intelligence to automate laboratory processes. ISO 13485 regulatory expertise ensures the clinical compliance of the produced devices. In January 2026, the acquisition of Myriade completed this portfolio with the VIDEODROP technology, a label-free nano-bioanalysis tool for characterizing nanoparticle size and concentration.

The Inside Therapeutics Partnership: Operational Synergy

In October 2025, MGA MedTech entered into an industrial agreement with Inside Therapeutics, a French TechBio company founded in 2022. This partnership combines InsideTX’s expertise in lipid nanoparticle (LNP) formulation with MGA MedTech’s industrialization capabilities.

The TAMARA Platform: Optimizing RNA R&D

The TAMARA system is designed to streamline the preclinical R&D workflow for RNA-LNP therapies.

• Integrated Solution: The system covers the entire preclinical workflow on a single platform, with an operating range of 200uL to 30 mL.
• Economic Efficiency: The fluidic design allows for nearly 100% sample recovery, minimizing the loss of expensive reagents. The use of reusable microfluidic chips significantly reduces laboratory operational costs.
• Technical Specifications: The technology relies on a dual-geometry mixing chip (Herringbone and Baffle), allowing nanoparticle size adjustment from 50 to 300 nm with a Polydispersity Index (PDI) below 0.2. Encapsulation efficiency reaches 98% with superior reproducibility (less than 3% variation between batches).

Industrial Role and Health Sovereignty

MGA MedTech ensures the transition from prototype to industrial production while maintaining strict tolerances and ISO 13485 standards. Both entities consider the “human fit” of the teams a success factor for a long-term industrial relationship. This collaboration supports health sovereignty objectives by accelerating access to RNA therapies for treating cancers and rare genetic diseases. Initial TAMARA units were delivered in September 2025 to stakeholders such as Institut Pasteur, Utrecht University or UPENN.

About

Inside Therapeutics (Inside Tx) is a french start up based in Bordeaux (France). The company designs, develops and markets instruments and services for manufacturing RNA-based lipid nanoparticles and liposomal products.

MGA MedTech is a French specialist in the industrialization and production of high-precision medical devices. Based in Mably, the company applies its engineering expertise, Industry 4.0 facility, and mastery of quality processes to serve medical innovations.

References

[1] https://vitrinesindustriedufutur.org/lalliance-industrie-du-futur-labellise-deux-nouvelles-vitrines-industrie-du-futur-%F0%9F%91%8F/

[2] https://www.mga-medtech.com/

[3] https://www.maisonmga.fr/actualites/mga-medtech-inside-therapeutics-industrial-partnership-serving-innovation-nanomedicine/